Financial cost and quality of life of patients with spinal muscular atrophy identified by symptoms or newborn screening.
Tamara DangouloffMickael HiligsmannNicolas DeconinckAdèle D'AmicoAndreea M SeferianJuliana R ConstanteLaurent ServaisPublished in: Developmental medicine and child neurology (2022)
Untreated patients with spinal muscular atrophy had lower total financial costs than treated patients. Total financial costs were lower for treated patients identified by early screening than for treated patients identified after symptom onset. Direct financial costs excluding treatment were much lower in treated patients identified by early screening. Hospitalization costs were much lower in patients identified by early screening.